MIAMI, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced it has named Jerome Bailey as the company’s new vice president of business operations. He joins the company from Checkmate Pharmaceuticals (acquired by Regeneron), where he served as senior director of program management. Mr. Bailey brings to the company more than 30 years of operational leadership and program management experience in the biopharmaceutical industry, overseeing clinical trials from Phase 1 through Phase 4 across several therapeutic areas.
TARRYTOWN, N.Y., May 31, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully acquired Checkmate Pharmaceuticals, Inc., deepening its commitment to immuno-oncology and adding a new modality to the company's portfolio of potential combination-ready approaches for difficult-to-treat cancers.
In a 10-Q filed Thursday, Checkmate detailed the dire straits facing the company, which was hit hard by the COVID-19 pandemic. The global health crisis forced Checkmate to delay initiation of clinical trials and patient enrollment—a challenge that has continued to this day, according to the document.
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...
Announced Tuesday, the all-cash deal has Regeneron paying $10.50 per share of Checkmate Pharmaceuticals' common stock, for a total offer of $250 million. The companies expect the acquisition to close sometime in the middle of this year.
CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing its proprietary...
Alan Bash, experienced biopharmaceutical executive, appointed President and CEO Clinical trials with vidutolimod (CMP-001) in melanoma, head and neck cancer indications ongoing; Trial dosing...
CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing its proprietary...
Checkmate Pharmaceuticals has hired Bristol Myers Squibb SVP Alan Bash to run its chessboard as president and CEO, completing a more than three-month search for someone to fill the top post.
CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the addition of Jon Wigginton, M.D. to its Board of Directors (“Board”).